Drugs / I-123 radiolabeled metaiodobenzylguanidine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT01432626 | Sep 2011 → Dec 2014 | Tako-tsubo cardiomyopathy | University of Pittsburgh | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | I-123 radiolabeled metaiodobenzylguanidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01432626 ↗ |
| Known as | mIBG | “I-123 radiolabeled metaiodobenzylguanidine, (mIBG) imaging allows for direct analysis of cardiac sympathetic function because it is structurally similar to norepinephrine (NE),...” NCT01432626 ↗ |
| Modality | Diagnostic / imaging agent | “an imaging approach that specifically evaluates the sympathetic activation state of the myocardium” NCT01432626 ↗ |
| Route | Intravenous | “All subjects will receive an intravenous injection of 10 mCi (370 MBq) of 123I-mIBG.” NCT01432626 ↗ |